Difficulty: Medium
Average Score: 84%
Practice
A 79-year-old man with Alzheimer's disease is found to have significant elevation of liver function tests on routine follow-up examination. Which of the following medications should be maintained at current doses in this patient?
Correct answer
C
Rationale
In a 79-year-old man with Alzheimer's disease and elevated liver function tests, maintaining Rivastigmine at the current dose is the optimal choice. Rivastigmine is metabolized primarily by cholinesterase and is less dependent on liver metabolism compared to other drugs like Donepezil, Galantamine, and Tacrine. This makes Rivastigmine a safer option in patients with liver impairment as its clearance is not significantly affected by liver function.
Donepezil, Galantamine, and Tacrine are predominantly metabolized by the liver, and in a patient with liver function abnormalities, these drugs can potentially exacerbate liver damage or cause adverse effects due to impaired metabolism and elimination. Therefore, it is not advisable to maintain these drugs at the current doses in a patient with elevated liver function tests.
From an educational perspective, understanding the metabolic pathways of CNS drugs is crucial in clinical decision-making, especially in patients with comorbidities like liver dysfunction. It is essential for healthcare providers to consider the pharmacokinetic profiles of medications to individualize treatment plans and minimize the risk of adverse effects or drug interactions, particularly in vulnerable populations like the elderly with multiple health conditions. In this case, selecting Rivastigmine aligns with the principle of choosing the safest therapeutic option based on the patient's liver function status.
Donepezil, Galantamine, and Tacrine are predominantly metabolized by the liver, and in a patient with liver function abnormalities, these drugs can potentially exacerbate liver damage or cause adverse effects due to impaired metabolism and elimination. Therefore, it is not advisable to maintain these drugs at the current doses in a patient with elevated liver function tests.
From an educational perspective, understanding the metabolic pathways of CNS drugs is crucial in clinical decision-making, especially in patients with comorbidities like liver dysfunction. It is essential for healthcare providers to consider the pharmacokinetic profiles of medications to individualize treatment plans and minimize the risk of adverse effects or drug interactions, particularly in vulnerable populations like the elderly with multiple health conditions. In this case, selecting Rivastigmine aligns with the principle of choosing the safest therapeutic option based on the patient's liver function status.